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Abstract
Objectives To explore the impact of sex and age on relationship between prodromal constipation and disease phenotype in 
Parkinson’s disease at early stages.
Methods A total of 385 Parkinson’s disease patients from the PRIAMO study were classified according to the presence of 
prodromal constipation and followed for 24 months. Multivariable mixed-effect models were applied. All analyses were 
performed separately for sex (64.1% men) and median age (different by sex: 67 years-old in men and 68 years-old in women).
Results As for sex, prodromal constipation was associated with greater odds of attention/memory complaints and apathy 
symptoms in women only. As for age, prodromal constipation was associated with lower cognitive and higher apathy scores 
in older patients only.
Conclusions Prodromal constipation anticipates lower cognitive performances and more severe apathy since the earliest 
stages in women and older patients. Sex- and age-related heterogeneity of prodromal markers of Parkinson’s disease may 
impact disease phenotype.
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EQ-VAS  EuroQol visual analogue scale
HAM  Hamilton depression scale
HRQol  Health-related quality of life
H&Y  Hoehn and Yahr
LR  Likelihood ratio
MDS  The movement disorder society
MMSE  Mini Mental State examination
NMS  Non-motor symptoms
OR  Odds ratio
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Introduction
The Movement Disorder Society (MDS) research criteria 
for prodromal Parkinson’s disease (PD) provide a meth-
odological framework to estimate the likelihood of devel-
oping the disease based on the presence of specific features 
[1]. Such criteria have been validated in prospective cohort 
studies as well as in primary care settings [2, 3]. As sex 
and age may impact the predictive value of single risks 
and prodromal markers of PD, both such factors need to 
be considered when developing risk models and tools for 
earlier detection of the disease [4].
Constipation represents one of the most solid prodromal 
markers of PD (positive likelihood ratio, LR + = 2.5) [1]. 
Recent evidence suggests higher odds of developing PD for 
women and subjects with constipation aged above 65 year-
old [4]. However, constipation is a common gastrointesti-
nal disorder in general population with prevalence up to 
30% and, similarly to PD, more prevalent in women and 
elderly [5–7]. Both the presence of gastrointestinal patho-
logical α—synuclein deposits and constipation in prodromal 
and clinically established PD suggests an integral role of 
the gut—brain axis for the early pathogenesis of the dis-
ease. According to such hypothesis, the synucleinopathy is 
hypothesized to ascend via the vagal nerve from peripheral 
neurons of the gastrointestinal tract to the brain [1–4, 8, 9].
To date, it is unknown if in PD the higher prevalence 
of prodromal constipation may have an impact on disease 
phenotype and progression. As such, no data is available 
on the relationship between the presence of prodromal 
constipation (PC) and disease phenotype at early stage.
By further analyzing prospective data from a subset of 
patients of the PRIAMO (PaRkinson dIseAse non-MOtor 
symptoms) study [10, 11] the present work aims to explore 
the relationship between the presence of prodromal consti-
pation and disease phenotype in the early stages consider-
ing the impact of sex and age.
Patients and methods
Patients and assessments
This study involves a subgroup of patients from the PRI-
AMO study. The PRIAMO study is a large Italian multi-
centre observational study designed to assess the prevalence 
and evolution of NMS in patients affected by different par-
kinsonian syndromes and including a cross sectional and a 
longitudinal prospective 24-month phase [12–14].
Study methods and patient baseline features have 
been extensively described elsewhere [10, 11]. Each 
patient underwent a baseline (T1) and two follow-up vis-
its, at 12 months (± 4) after the baseline visit (T2) and 
9-16 months after the first follow-up visit (T3), respec-
tively. Diagnosis of idiopathic PD was based on Gelb 
et al., criteria. Enrolled patients were administered a semi-
structured interview exploring 12 NMS domains (gastro-
intestinal, urinary, pain, cardiovascular, sleep, fatigue, 
apathy, attention/memory complaints, skin, psychiatric, 
respiratory and other symptoms including smell and taste 
impairment, diplopia, weight change), each one includ-
ing 2–10 specific questions with dichotomous (yes/no) 
answers (see supplemental material online) [10, 11].
In addition, only patients reporting gastrointestinal 
dysfunction in the semistructured interview were asked if 
they had developed constipation before the onset of motor 
symptoms (yes/no). All the clinicians involved were expert 
in movement disorders and participated in a training session 
before starting enrolment for the PRIAMO study.
The Unified Parkinson’s Disease Rating Scale-part III 
(UPDRS-III) was used to evaluate motor disability, while 
cognitive abilities were investigated with the Mini-Mental 
State Examination (MMSE). Depressive symptoms were 
evaluated with the Hamilton Depression scale (HAM). HR-
Qol was investigated using the 39-item Parkinson’s disease 
questionnaire (PDQ-39) and the EuroQol visual analogue 
scale (EQ-VAS).
For this subanalysis, only patients with early stage PD 
[namely, Hoehn and Yahr (H&Y) stage ≤ 2] at baseline, 
with no missing answers to the gateway question on PC, 
and with at least one follow-up assessment were considered. 
The study was approved by the ethics committees of the par-
ticipating centers and all patients provided written informed 
consent.
Statistical analysis
Of 1142 PD patients enrolled in the PRIAMO study, 385 
(247 men and 138 women) PD patients had H&Y stage ≤ 2 
at baseline and with no missing answers to the gateway ques-
tion on PC and at least one follow-up assessment, and, thus, 
were eligible for the present analysis. Data at follow-up were 
available for 322 patients (of whom 209 men) at T2 and 297 
patients (of whom 193 men) at T3.
Given the aim of the present work, all the analyses were 
performed separately for sex (64.1% men) and median age 
by sex (i.e., 67 years in men and 68 years in women).
After checking for normal distribution of variables, com-
parisons between groups were performed using χ2, t test 
and analysis of variance (ANOVA) as appropriate. Accord-
ingly, descriptive statistics are presented as proportions, or 
mean and standard deviation (SD). To test the association 
between PC (the independent variable) and NMS, L-dopa 
treatment, UPDRS-III, MMSE, HAM, PDQ-39 and EQ-VAS 
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(modelled as the dependent variables) over time, we used 
multivariate mixed effect logistic (for categorical variables: 
NMS and L-dopa treatment) and linear (for continuous vari-
ables: UPDRS-III, MMSE, HAM, PDQ-39 and EQ-VAS) 
regression models fitted with random patients intercept and 
adjusted for disease duration, time point and, according to 
the specific model, patients’ age or sex. A part from the sep-
arate analysis on the impact of age considered as a binomial 
variable, age was included as a continuous variable (refer 
to supplemental material for detailed results). Considering 
the possible role of both age and sex as effect modifiers in 
association with our study outcomes, in our model build-
ing strategy we also tested for an interaction term between 
age and sex. However, the interaction term was not signifi-
cant. Hence, the interaction was excluded from the model to 
reduce degrees of freedom.
Associations were considered significant if p-values were 
lower than 0.05. Coefficients are presented as adjusted esti-
mates (continuous dependent variables) or odds ratios (cat-
egorical dependent variables) along with 95% confidence 
intervals (95% CI).
Statistical analyses were performed using the lme4 pack-
age in the R software (version 3.4.1).
Results
Detailed demographic and clinical features of the included 
cohort by sex at T1, T2 and T3 are displayed in Supplemen-
tal material online.
Relationship with sex
Prevalence of PC was 34% in men and 45.6% in women 
(p = 0.024). In women, PC was associated with greater 
odd of endorsing attention/memory complaints (OR: 4.35, 
95%CI: 1.13–16.72, p = 0.032) and apathy (OR: 3.49, 
95%CI: 1.05–11.59, p = 0.041) domain, lower probability of 
being treated with levodopa (OR: 0.12, 95%CI: 0.02–0.76, 
p = 0.025) and a trend towards significance for lower MMSE 
scores (coeff.: − 1.45, 95%CI: − 2.94 to 0.03, p = 0.055). 
Conversely, in men PC was only associated with lower prob-
ability of complaining of other NMS (OR: 0.35, 95%CI: 
0.13–0.94, p = 0.037) (Table 1).
Relationship with age
Prevalence of PC was 38.7% in younger and 40.4% in 
older patients (p = 0.084). In older patients, PC was associ-
ated with greater odds of being treated with L-dopa (OR: 
11.58, 95%CI: 1.85–72.40, p = 0.009) and complaining 
about apathy (OR: 7.34, 95%CI: 1.79–30.07, p = 0.006). 
There was also a trend towards significance for greater 
odds of attention/memory complaints (OR: 3.46, 95%CI: 
0.96–12.49, p = 0.057) and a significant association with 
lower MMSE (coeff.: − 2.48, 95%CI: − 4.00 to − 0.96, 
p = 0.001) and higher HAM (coeff.: 2.07, 95%CI: 0.51–3.62, 
p = 0.009) (Fig. 1a, b). Conversely in younger patients, no 
significant association was detected (Table 1).
Discussion
In the present prospective longitudinal study, we explored 
the association between the presence of PC and disease phe-
notype in the early stages considering the impact of sex and 
age in a large cohort of PD patients.
In line with previous evidence, our cohort presented an 
overall prevalence of PC of approximately 40%, with higher 
frequency in women and older patients [4, 15]. When exam-
ining the impact of sex, the presence of PC was associated 
with attention/memory complaints and apathy as well as 
with a trend towards significance for lower cognitive per-
formances in women only. Complementary, when consid-
ering the impact of age, the presence of PC was associated 
with attention/memory complaints and apathy, higher rates 
of treatment with levodopa as well as with lower cognitive 
performances and more severe apathy in older patients only 
(Fig. 1a, b).
Previous evidence showed high sex- and age-related het-
erogeneity of several prodromal markers of PD supporting 
the notion that such demographic factors should be taken 
into account when evaluating tools or algorithms for PD 
prediction [2–4]. Accordingly, PC confers greater risk of 
developing PD in women and healthy subjects aged above 
65 year-old [4]. On the other hand and similarly to other 
autonomic symptoms, once the motor symptoms have mani-
fested, the presence of constipation since the early phase 
represents a risk factor for a more severe motor and cogni-
tive burden of disease [16–18]. Notwithstanding, to date, 
evidence suggesting a relationship between the presence 
of constipation in prodromal phase and disease phenotype 
after onset of motor symptoms are lacking. Here, we demon-
strated that PC might anticipate a specific phenotype of the 
disease characterized by early involvement of cognitive and 
behavioural domains especially in women and older patients. 
Also, irrespective of sex, older patients reporting PC have 
higher odds of receiving levodopa reflecting a greater motor 
burden of disease.
Also in line with the hypothesis of a gut-brain axis, the 
role of PC as a prodromal symptom for PD seems to confirm 
the Braak’s model for the progression of Lewy pathology, 
with an early involvement of the enteric nervous system and 
dorsal motor nucleus of the vagus even before degeneration 
of substantia nigra begins [8, 9, 16]. Accordingly, PC is con-
sidered one of the earliest marker of autonomic dysfunction 
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in PD. As such our findings are in line with previous data 
suggesting that early autonomic dysfunction has to be con-
sidered as a risk marker for a more severe form of disease 
since the earliest stages [13, 16–19]. Recent evidence sug-
gests several risk and prodromal markers of PD (including 
constipation, male sex and age) are associate with diverse 
gut microbiome composition further supporting the piv-
otal role of the gut-brain axis in disease pathogenesis [20]. 
Our data demonstrate for the first time (1) the association 
between PC and early disease phenotype as well as (2) the 
sex- and age-dependency of such relationship.
We acknowledge our study has limitations. First, the lack 
of a longer longitudinal phase precludes the possibility of 
describing the complete natural history of PD patients with 
PC. Notwithstanding, this is the largest study to date eval-
uating prospectively the sex- and age-related relationship 
between PC and both motor and non-motor symptoms in 
early PD. Second, as the presence of prodromal constipa-
tion was annotated with a patient interview, we recognize 
the possibility of a recall bias. Similarly the majority of 
non-motor symptoms were evaluated with a semistructured 
interview and not with objective testing. However, global 
cognition and depression were evaluated with validated 
scales. Although we recognize the sample drop at follow-up 
as a further limitation, mixed-effect regression model should 
handle missing data to some extent. Finally, the lack of a 
control group from the general population represents another 
drawback as constipation is highly frequent in the general 
population, especially in women and older subjects. Thus, 
we cannot exclude such findings are detected also in healthy 
controls. A large body of evidence show the influence of sex 
and age on both prevalence as well as pattern of constipation 
symptoms [21]. Future studies should investigate the impact 
of demographic features on specific symptoms of consti-
pation in PD compared to general population. Also, recent 
evidence suggests a complex interaction between microbial 
composition and risk and prodromal markers of PD with sex 
and age being associated with different microbial measures 
[20]. Thus, we are aware we are describing only part of a 
manifold framework. Notwithstanding, this is the first study 
attempting at describing the impact of sex and age on the 
relationship between PC and phenotype of disease.
In conclusion, we demonstrated that PC anticipates lower 
cognitive performances and more severe apathy since the 
Fig. 1  Age dependence of predictive values of prodromal constipa-
tion (PC) for higher Hamilton Depression scale (HAM) (a) and lower 
Mini-mental State Examination (MMSE) (b). Error bars indicate 95% 
confidence intervals. Asterisks indicate significant interaction effect 
in linear regression models (p < 0.05)
 Journal of Neurology
1 3
earliest stages of PD in women and older patients. In addi-
tion, older patients reporting PC might present a greater 
motor burden of disease. Sex- and age-related heterogeneity 
of prodromal markers of PD may have an impact on disease 
phenotype.
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